2134 completed, 673 terminated, 621 recruiting, 514 unknown. 2037 Phase 2, 1740 Phase 1, 457 Phase 3, 332 Not applicable, 83 Phase 4.
Follow Leukemia, Myeloid: new trials by email Literature Review of Leukemia, Myeloid trials Research Report on Leukemia, Myeloid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pyronaridine in Acute Myeloid Leukemia (AML) Pyronaridine Tetraphosphate - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 2 | Suspended | Armaceutica, Inc. | 200 | 2028-02-21 | 2026-10-19 |
| Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion, Gemtuzumab Ozogamicin - Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1 | Not yet recruiting | German Cancer Research Center | 12 | 2028-01-01 | 2025-03-14 |
| A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) Cytarabine, Oral Cladribine - Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 58 | 2027-12-01 | 2026-08-25 |
| Universal CAR-T Cells Targeting AML CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells - Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-08-27 |
| Universal 4SCAR7U Targeting CD7-positive Malignancies Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-08-26 |
| A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia GT737 Injection - Relapsed/Refractory Acute Myeloid Leukemia (AML) | Early Phase 1 | Not yet recruiting | Grit Biotechnology | 36 | 2027-05-01 | 2026-09-11 |
| Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML Decitabine, Venetoclax, Axatilimab - Acute Myeloid Leukemia, TP53 Gene Mutation | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 32 | 2027-01-31 | 2026-10-16 |
| Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 122 | 2027-01-15 | 2026-10-07 |
| Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 244 | 2027-01-15 | 2026-10-20 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| CD34+ Transplants for Myeloid Malignancies Busulfan, Melphalan, Fludarabine - Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute | Phase 2 | Not yet recruiting | Guenther Koehne | 50 | 2027-01-01 | 2026-10-13 |
| Feasibility and Efficiency Study for the Implementation of a New Screening Method for Patients With Acute Myeloid Leukemia, in Laboratory Practice Bone marrow or peripheral blood withdrawal for test comparison - Acute Myeloid Leukemia, Acute Myeloid Leukemia, Adult | Not applicable | Not yet recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 75 | 2027-01-01 | 2026-10-09 |
| Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome Monzosertib, Posaconazole, Isavuconazole - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 42 | 2027-01-01 | 2026-08-21 |
| Asciminib Frontline Risk Adapted Dasatinib 80mg QD (5 days per week), Standarc of Care - Chronic Myeloid Leukemia (CML) | Phase 2 | Not yet recruiting | Prof. Dr. med. Andreas Hochhaus | 200 | 2027-01-01 | 2026-09-04 |
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms Oral THU-decitabine - Myelofibrosis, MPN - Accelerated or Blast Phase | Phase 2 | Not yet recruiting | John Mascarenhas | 20 | 2027-01-01 | 2026-10-14 |
| Improving Delivery of Aging-Related Supportive Care for Older Adults With Acute Myeloid Leukemia Active Default - Acute Myeloid Leukemia (AML) | Not applicable | Not yet recruiting | University of Alabama at Birmingham | 40 | 2027-01-01 | 2026-10-13 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| Prevention of Oral Mucositis in Adults in With Hematologic Malignancy Aloe Vera Mouthwash, Standard of Care - Acute Leukemia, Acute Myeloid Leukemia | Not applicable | Not yet recruiting | Wake Forest University Health Sciences | 206 | 2027-01-01 | 2026-10-22 |
| Multi-CAR T Cell Therapy for Acute Myeloid Leukemia Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2026-12-31 | 2026-08-26 |
Showing 20 of 4653. Sign in to see all of them.
Leukemia, Myeloid, Acute (3585) · Myelodysplastic Syndromes (1253) · Leukemia (1038) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (983) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (877) · Leukemia, Myelomonocytic, Chronic (540) · Lymphoma, Non-Hodgkin (477) · Leukemia, Lymphocytic, Chronic, B-Cell (476) · Leukemia, Myeloid, Chronic-Phase (439) · Multiple Myeloma (415) · Hodgkin Disease (406) · Myeloproliferative Disorders (406) · Congenital Abnormalities (396) · Recurrence (360) · Blast Crisis (356)
Hemic and Lymphatic Diseases (4653) · Neoplasms by Histologic Type (4639) · Hematologic Diseases (4597) · Neoplasms (4487) · Leukemia (3615) · Bone Marrow Diseases (2405) · Pathological Conditions, Signs and Symptoms (2026) · Pathologic Processes (2009) · Disease Attributes (1942) · Chronic Disease (1704) · Immune System Diseases (1290) · Immunoproliferative Disorders (1230) · Lymphatic Diseases (1214) · Lymphoproliferative Disorders (1201)
Cytarabine (635) · Azacitidine (448) · Cyclophosphamide (357) · venetoclax (345) · fludarabine phosphate (288) · fludarabine (276) · Busulfan (225) · Decitabine (213) · Peripheral Blood Stem Cell Transplantation (176) · Idarubicin (175) · Daunorubicin (172) · Imatinib Mesylate (171) · Mycophenolic Acid (171) · Filgrastim (169) · Whole-Body Irradiation (160)
M.D. Anderson Cancer Center (270) · National Cancer Institute (NCI) (192) · Fred Hutchinson Cancer Center (141) · Novartis Pharmaceuticals (130) · City of Hope Medical Center (72) · Masonic Cancer Center, University of Minnesota (68) · Memorial Sloan Kettering Cancer Center (67) · The First Affiliated Hospital of Soochow University (53) · Children's Oncology Group (49) · Gruppo Italiano Malattie EMatologiche dell'Adulto (49) · Institute of Hematology & Blood Diseases Hospital, China (44) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (44) · Washington University School of Medicine (43) · AbbVie (42) · Bristol-Myers Squibb (42)
United States (2690) · China (528) · France (485) · Germany (405) · Italy (352) · Canada (306) · Spain (278) · United Kingdom (232) · Australia (202) · South Korea (180) · Belgium (157) · Netherlands (148) · Japan (112) · Poland (112) · Israel (105)
Jorge Cortes, MD (25) · Brenda Sandmaier (18) · Farhad Ravandi-Kashani, MD (15) · Jorge E Cortes, MD (12) · Courtney DiNardo, MD (11)
PMID 32499241, PMID 33394722, PMID 24383844, PMID 25527568, PMID 35235189, PMID 36064577, PMID 36184192, PMID 23524640, PMID 23620574, PMID 28835440, PMID 30885996, PMID 42013378, PMID 23065508, PMID 22965967, PMID 24923295, PMID 25361995, PMID 30062662, PMID 31171508, PMID 31375516, PMID 35829925, PMID 35982483, PMID 37267439, PMID 37341189, PMID 38507688, PMID 20705755, PMID 20965785, PMID 22825216, PMID 23841729, PMID 27400247, PMID 27400939, PMID 29702001, PMID 29859851, PMID 32786187, PMID 34699069, PMID 35007144, PMID 35790816, PMID 36815378, PMID 37093350, PMID 37553873, PMID 38295280, PMID 38429079, PMID 39133921, PMID 39368878, PMID 40073835, PMID 42085603, PMID 16775234, PMID 17151364, PMID 17715389, PMID 18824593, PMID 18997171
P30CA015704 (64), P30CA033572 (49), P30CA006973 (36), 2018 (29), 2023 (26), P30CA016672 (25), U10CA032102 (24), 2015 (23), P01CA018029 (23), U10CA031946 (23), P30CA043703 (22), U01CA070095 (21), 2014 (20), 2025 (20), 2016 (19)